Maryland's pharmaceuticals companies operate at the intersection of science and innovation, focusing on research and development to create medicines that address critical health needs. The industry spans various sectors, including biopharmaceuticals, generics, and specialized therapies, often targeting unique medical conditions ranging from rare diseases to oncology. As public interest in health solutions grows, these companies are honing their approaches, emphasizing personalized medicine and cutting-edge technologies. With substantial investment and strategic partnerships, Maryland's pharmaceutical sector is poised for advancement, producing breakthrough treatments that can change lives.

The companies listed here represent a robust pharmaceutical sector in Maryland, showcasing sizes from small startups to large biopharmaceutical firms. Headquarters are spread across key locations, including Gaithersburg, Rockville, and Baltimore, and span foundational years from 1957 to 2020. Their specializations vary widely from generic drugs and immunotherapy to advanced biotechnology and vaccine development. This variety reflects a dynamic industry, adapting to clientele needs and forefronting innovative research.

Continue reading to discover the top pharmaceuticals companies in Maryland.

Top 25 Pharmaceuticals Companies Companies in Maryland

1. MedImmune

• Website: medimmune.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 78%, United Kingdom (UK) 18%, Other 4%
• Latest funding: $15.6B, April 2007
• Founded year: 1987
• Headcount: 1001-5000
• LinkedIn: medimmune

MedImmune, founded in 1987 and based in Gaithersburg, Maryland, is a biopharmaceutical company that operates as a subsidiary of AstraZeneca. The company specializes in the research and development of innovative medicines across various therapeutic areas, including oncology, cardiovascular, and respiratory diseases. MedImmune is dedicated to improving health outcomes through its extensive pipeline of products and a strong focus on sustainability. With a workforce of approximately 960 employees, the company is primarily located in the United States, with a significant presence in the United Kingdom. MedImmune's commitment to advancing healthcare is evident in its strategic initiatives and partnerships aimed at addressing unmet medical needs and enhancing patient care.

2. Amplimmune, Inc.

• Website: amplimmune.com
• Ownership type: Corporate
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $500.0M, August 2013
• Founded year: 2006
• Headcount: 1001-5000
• LinkedIn: amplimmune-inc.

Amplimmune, Inc. is a biopharmaceutical company based in Rockville, Maryland, founded in 2006. The company specializes in the research and development of innovative medicines, focusing primarily on oncology and rare diseases. Amplimmune aims to provide advanced treatments through clinical trials, contributing to improved health outcomes for patients. As a subsidiary of AstraZeneca, Amplimmune benefits from the larger company's resources and expertise, although this affiliation may also affect its individual recognition in the industry. The company has received substantial funding, amounting to $500 million, which underscores its potential in the biopharmaceutical sector, despite the lack of recent updates on its activities or product pipeline.

3. TopAlliance Biosciences Inc

• Website: topalliancebio.com
• Ownership type: Private Equity
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 78%, Singapore 13%, China 9%
• Latest funding: January 2014
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: topalliance-biosciences-inc

TopAlliance Biosciences Inc, founded in 2013 and based in Rockville, Maryland, is a biopharmaceutical company dedicated to the discovery and development of innovative drugs, with a strong emphasis on oncology. The company operates through advanced research and development processes and has established manufacturing capabilities to support its drug development efforts. Their flagship therapy, LOQTORZI™ (also known as TUOYI™ in China), is an anti-PD-1 monoclonal antibody that has shown promising clinical results and has been approved by the FDA for use in treating recurrent or metastatic nasopharyngeal carcinoma. TopAlliance is committed to bringing novel therapies to patients in need, leveraging its research platforms and a global operational footprint that includes significant presence in the U.S., Singapore, and China. The company is part of a broader network of innovative drug development, with its parent company, Shanghai Junshi Biosciences, being a pioneer in the Chinese biopharmaceutical sector.

4. Leadiant Biosciences, inc.

• Website: leadiant.com
• Ownership type: Private
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 79%, Italy 21%
• Founded year: 1957
• Headcount: 51-200
• LinkedIn: sigma-tau-pharmaceuticals-inc-

Leadiant Biosciences, Inc. is a private pharmaceutical company based in Gaithersburg, Maryland, established in 1957. The company is dedicated to the research, development, and distribution of therapies specifically targeting rare diseases. With a workforce of approximately 53 employees, Leadiant emphasizes innovative solutions that cater to the unique health challenges faced by patients. Their product portfolio includes notable medications such as Abelcet® (amphotericin B lipid complex injection), Carnitor® (levocarnitine), Cystaran® (cysteamine ophthalmic solution), and Matulane® (procarbazine hydrochloride). Leadiant's commitment to patient care is evident in their efforts to provide resources and support for patients and caregivers, ensuring that their voices are heard in the drug development process. The company operates primarily in the United States, with a significant presence in Italy, reflecting its international reach in addressing rare diseases.

5. Jubilant Cadista Pharmaceuticals

• Website: cadista.com
• Ownership type: Corporate
• Headquarters: Salisbury, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: December 2014
• Founded year: 2005
• Headcount: 201-500
• LinkedIn: jubilantcadista-pharmaceuticals

Jubilant Cadista Pharmaceuticals Inc. is a pharmaceutical company based in Salisbury, Maryland, established in 2005. The company is dedicated to the development, manufacture, and distribution of generic medications, aiming to provide high-quality and affordable pharmaceuticals to healthcare providers and pharmacies. With a workforce of approximately 138 employees, Jubilant Cadista emphasizes quality in every aspect of its operations, from formulation development to distribution. Their product offerings span various therapeutic categories, including CVS, CNS, GI, anti-inflammatory, and anti-allergy medications. The company operates with a strong commitment to customer service, ensuring transparency and swift issue resolution. Their manufacturing capabilities are supported by a facility in Roorkee, India, which services both the U.S. market and international clients. This strategic positioning allows Jubilant Cadista to effectively address the needs of patients and healthcare providers alike.

6. Immunomic Therapeutics, Inc.

• Website: immunomix.com
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $3.0M, April 2024
• Founded year: 2005
• Headcount: 11-50
• LinkedIn: immunomic-therapeutics-inc-

Immunomic Therapeutics, Inc. is a clinical-stage biotechnology firm based in Rockville, Maryland. Founded in 2005, the company specializes in the development of immunotherapies and vaccines, primarily targeting critical medical needs in oncology. Their proprietary technology platform, UNITE® (UNiversal Intracellular Targeted Expression), is designed to leverage the body's natural immune responses to create effective treatments for various cancers. Immunomic Therapeutics is currently advancing several clinical trials, including those for glioblastoma multiforme and Merkel cell carcinoma, indicating a strong focus on oncology. The company collaborates with notable research institutions, such as the University of Florida and Dana Farber Cancer Institute, to enhance its research capabilities and expedite the development of its therapies. Recently, they secured $3 million in funding, reflecting continued investor confidence in their innovative approach to cancer treatment.

7. On Demand Pharmaceuticals Inc

• Website: ondemandpharma.com
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: ondemandpharma

On Demand Pharmaceuticals Inc, based in Rockville, Maryland, is a private pharmaceutical company established in 2016. The firm specializes in agile medicine-making capabilities, aiming to provide affordable medications to healthcare professionals and organizations. Their innovative solutions include subscription services, termed 'Medications as a Service,' and point-of-care delivery systems, known as 'Pharmacy on Demand.' These initiatives are designed to streamline access to medications, particularly in response to drug shortages. The company is committed to developing high-quality medications while advocating for fair pricing and transparency in the pharmaceutical supply chain. Their recent collaborations, such as partnerships with North Mississippi Health Services, highlight their proactive approach to addressing healthcare challenges and enhancing medication accessibility.

8. VERALOX Therapeutics

• Website: veralox.com
• Ownership type: Venture Capital
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $24.0M, June 2023
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: veralox-therapeutics

VERALOX Therapeutics, founded in 2018 and based in Frederick, Maryland, is a biotechnology firm dedicated to developing innovative therapies for life-threatening immuno-inflammatory diseases. The company is currently advancing its lead product, VLX-1005, which targets heparin-induced thrombocytopenia (HIT). This first-in-class small molecule inhibitor has shown promise in preclinical studies, halting immune-driven platelet activation and thrombosis. In recognition of its potential, VLX-1005 has received orphan drug designations from both the FDA and EMA, highlighting the urgent need for effective treatments in this area. With a small team of around 18 employees, VERALOX is agile and focused, actively engaging in research and development to meet significant healthcare challenges. The company recently raised $24 million in funding, further supporting its mission to bring new therapies to market.

9. BioFactura, Inc.

• Website: biofactura.com
• Ownership type: Corporate
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $1.0M, July 2020
• Founded year: 2003
• Headcount: 11-50
• LinkedIn: biofactura-inc-

BioFactura, Inc. is a biopharmaceutical company based in Frederick, Maryland, established in 2003. The company specializes in the development and manufacturing of high-value biosimilars and biodefense medical countermeasures. BioFactura aims to meet unmet medical needs through innovative drug development, particularly targeting therapeutics for smallpox and Marburg virus. Their clientele includes government agencies and healthcare organizations seeking effective treatments against biological threats. The company has developed the StableFast Biomanufacturing Platform, which enhances the efficiency and quality of biopharmaceutical production. BioFactura has received funding, including a notable $1 million grant in 2020, to support its initiatives in drug development and manufacturing. Their ongoing projects and collaborations highlight their commitment to advancing healthcare solutions.

10. Nobelpharma America, LLC

• Website: nobelpharma-us.com
• Ownership type: Private
• Headquarters: Bethesda, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: nobelpharma

Nobelpharma America, LLC, established in 2019 and based in Bethesda, Maryland, is a private pharmaceutical company dedicated to developing critical drugs and medical devices for rare and underserved medical conditions. As a subsidiary of Nobelpharma Co., Ltd., which originated in Japan, the company aims to fill treatment gaps that larger pharmaceutical firms often overlook due to the limited patient populations. Nobelpharma America operates with a patient-first philosophy, striving to bring innovative solutions to healthcare providers and patients alike. Their pipeline includes products that have received approval in Japan, although they are still in the investigational phase in the U.S. market. The company emphasizes collaboration with global experts to expedite the development and delivery of essential medicines, reflecting a commitment to improving patient care in areas that lack sufficient treatment options.

11. WES Pharma Inc

• Website: wespharma.com
• Ownership type: Private
• Headquarters: Westminster, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2012
• Headcount: 11-50
• LinkedIn: wes-pharma-inc

WES Pharma Inc, founded in 2012 and based in Westminster, Maryland, is a private pharmaceutical company that specializes in the development and manufacturing of challenging specialty generics. With a workforce of around 34 employees, WES Pharma focuses on both over-the-counter (OTC) and prescription (Rx) solid and liquid dosage forms. The company operates from a 32,000 square foot facility that adheres to current Good Manufacturing Practices (cGMP), ensuring high-quality production standards. WES Pharma's product pipeline includes a variety of formulations such as tablets, capsules, solutions, and suspensions, particularly targeting complex molecules that present solubility and stability challenges. Their R&D efforts are supported by a skilled team of scientists who utilize advanced techniques to optimize drug delivery systems. WES Pharma also collaborates with other pharmaceutical entities to enhance their development and marketing capabilities, demonstrating their active engagement in the pharmaceutical sector.

12. OncoC4, Inc.

• Website: oncoc4.com
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 97%, Australia 3%
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: oncoc4

OncoC4, Inc. is a biopharmaceutical company based in Rockville, Maryland, specializing in the development of advanced cancer therapies. Founded in 2020, OncoC4 is dedicated to creating first-in-class and best-in-class medicines that target immune checkpoints, aiming to improve the immune response against various cancers. The company’s pipeline includes several innovative programs, such as their CTLA-4 antibody therapy, which is currently in clinical trials in collaboration with BioNTech. Their research also explores the potential of Siglec and CD24 platforms, which are designed to tackle the challenges of treating solid and hematologic malignancies. With a team of experienced scientists and a commitment to addressing the needs of patients with hard-to-treat cancers, OncoC4 is positioned to make a significant impact in the oncology field.

13. Revolo Biotherapeutics

• Website: revolobio.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United Kingdom (UK) 62%, United States (USA) 38%
• Latest funding: Series B, $52.0M, September 2020
• Founded year: 2011
• Headcount: 11-50
• LinkedIn: immune-regulation-limited

Revolo Biotherapeutics, founded in 2011 and based in Gaithersburg, Maryland, is a biotechnology firm dedicated to developing innovative therapies for autoimmune and allergic diseases. The company is focused on resetting the immune system to achieve long-lasting disease remission, which is a significant advancement over traditional treatments that often involve chronic dosing and immune suppression. Their lead candidates, '1104 and '1805, are designed to modify immune responses without the adverse effects commonly associated with existing therapies. '1104 is currently in Phase 2 trials for eosinophilic esophagitis, while '1805 is being tested for rheumatoid arthritis and ulcerative colitis. The company has successfully raised over $52 million in its latest funding round, reflecting strong investor interest in its unique approach to treating complex diseases. With a small but dedicated team, Revolo is positioned to make a notable impact in the biopharmaceutical industry.

14. Pii, A Jabil Company

• Website: pharm-int.com
• Ownership type: Corporate
• Headquarters: Cockeysville, Maryland, United States (USA)
• Employee distribution: United States (USA) 99%
• Latest funding: February 2025
• Founded year: 1994
• Headcount: 201-500
• LinkedIn: pharmaceutics-international

Pii, A Jabil Company, founded in 1994 and based in Cockeysville, Maryland, operates as a contract development and manufacturing organization (CDMO). The company specializes in providing a range of pharmaceutical and biotechnology services, including formulation and process development, analytical services, and quality assurance. With a workforce of approximately 362 employees, Pii has established itself as a reliable partner for drug manufacturers, assisting them in navigating the complexities of bringing new products to market. Their facilities are equipped to handle various drug formulations, including highly potent active pharmaceutical ingredients (HPAPIs) and biologics. Pii's commitment to quality and regulatory compliance ensures that they meet the evolving standards of the pharmaceutical industry, making them a valuable asset to their clients. Their focus on customized solutions and scientific expertise allows them to address the unique challenges faced by pharmaceutical companies, enhancing patient outcomes through effective drug development.

15. Rise Therapeutics

• Website: risetherapeutics.com
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), October 2024
• Founded year: 2017
• Headcount: 1-10
• LinkedIn: rise-therapeutics

Rise Therapeutics, founded in 2017 and based in Rockville, Maryland, is a biotechnology company dedicated to developing targeted immunological-based biologics. The company specializes in creating innovative oral immunotherapeutics aimed at treating chronic diseases such as autoimmunity, cancer, and infections. Rise Therapeutics leverages cutting-edge research in synthetic biology and microbiome science to drive its drug development efforts. Their proprietary Tripartite X (TPX) drug delivery platform enables the oral delivery of biologic therapies, which is a significant advancement in the field. Recently, the company received FDA clearance to initiate a Phase 1 clinical study for its candidate R-2487, aimed at treating rheumatoid arthritis. This milestone reflects their active role in the pharmaceutical industry and their commitment to bringing new therapies to market. Additionally, Rise Therapeutics has secured funding from organizations like TEDCO and the National Institutes of Health (NIH) to support their clinical development efforts, further solidifying their position in the biotech landscape.

16. Salubris Biotherapeutics

• Website: salubrisbio.com
• Ownership type: Corporate
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 83%, Vietnam 9%, China 9%
• Latest funding: Series A, $35.0M, April 2024
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: salubris-biotherapeutics

Salubris Biotherapeutics, Inc. is a biotechnology firm based in Gaithersburg, Maryland, established in 2016. The company specializes in the development of innovative biologics aimed at treating complicated diseases, with a strong focus on cardiovascular conditions and oncology. Salubris is recognized for its pioneering work, being the first to bring a bispecific antibody into clinical trials for cardiovascular indications. Their product pipeline includes promising candidates like JK06, a targeted antibody-drug conjugate for solid tumors, and JK07, an antibody fusion protein for heart failure. Salubris has actively engaged in clinical trials, demonstrating a commitment to advancing therapeutic options for patients. The company recently secured $35 million in Series A funding, which will bolster their research and development initiatives, further solidifying their role in the pharmaceutical landscape.

17. Georgiamune Inc.

• Website: georgiamune.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $75.0M, August 2023
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: georgiamune

Georgiamune Inc., founded in 2014 and based in Gaithersburg, Maryland, is a biopharmaceutical company dedicated to the development of innovative immunotherapeutics aimed at treating cancer and autoimmune diseases. The company specializes in reprogramming immune responses, focusing on restoring immune homeostasis through a pipeline of first-in-class drugs. Their portfolio includes several promising candidates, such as GIM-122, a dual-functioning antibody, and GIM-531, a Treg inhibitor, which are designed to tackle significant challenges in cancer treatment and autoimmune conditions. Georgiamune's recent Series A funding of $75 million in August 2023 underscores their potential and commitment to advancing their research. The company serves healthcare providers and pharmaceutical companies, positioning itself as a key player in the biopharmaceutical industry.

18. Rapafusyn Pharmaceuticals

• Website: rapafusyn.com
• Ownership type: Venture Capital
• Headquarters: Baltimore, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $28.0M, June 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: rapafusyn-pharmaceuticals

Rapafusyn Pharmaceuticals, founded in 2015 and based in Baltimore, Maryland, is a biotechnology firm dedicated to drug discovery and development. The company specializes in creating non-degrading molecular glues, known as RapaGlues™, which are designed to modulate difficult drug targets. Their platform utilizes large DNA-encoded libraries and arrayed libraries to generate novel chemical starting points for hard-to-drug targets, enhancing the potential for therapeutic development. Rapafusyn's focus on intracellular proteins and transmembrane proteins positions them to address significant challenges in drug discovery. Recently, they secured $28 million in Series A funding, which will support the advancement of their innovative drug discovery platform and further their mission to improve patient outcomes across various medical fields.

19. Integrated BioTherapeutics, Inc.

• Website: integratedbiotherapeutics.com
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Latest funding: $1.0M, May 2023
• Founded year: 2005
• Headcount: 11-50
• LinkedIn: integrated-biotherapeutics-inc.

Integrated BioTherapeutics, Inc. (IBT), founded in 2005 and based in Rockville, Maryland, is a biotechnology firm dedicated to the discovery and development of innovative vaccines and antibody therapeutics aimed at combating infectious diseases. The company specializes in creating solutions for emerging viral threats and antibiotic-resistant bacterial infections. Their product pipeline includes promising candidates such as a vaccine for Staphylococcus aureus, which is set to enter clinical trials in 2024, and monoclonal antibodies targeting Ebola and Marburg viruses. IBT collaborates with various government agencies, including the National Institute of Allergy and Infectious Diseases (NIAID) and the Department of Defense, to advance their research. In May 2023, IBT secured $1 million in funding, underscoring their active role in the biotechnology sector and commitment to addressing critical health challenges.

20. Remedy Plan Therapeutics

• Website: remedyplan.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $19.1M, August 2023
• Founded year: 2011
• Headcount: 1-10
• LinkedIn: remedy-plan

Remedy Plan Therapeutics, founded in 2011 and based in Gaithersburg, Maryland, is a biotechnology firm dedicated to developing innovative therapeutics that target NAMPT inhibition. This enzyme plays a crucial role in cellular metabolism, and its dysregulation is linked to over 20 diseases, including various cancers, autoimmune disorders, and obesity. Remedy Plan employs a proprietary drug screening platform to identify and optimize drug candidates, with a focus on minimizing toxicity—a significant challenge faced by previous NAMPT inhibitors. The company is currently advancing its lead candidate, RPT1G, through clinical trials, aiming to provide effective treatment solutions for patients. In August 2023, Remedy Plan secured approximately $19 million in funding, indicating investor confidence in their approach and potential. Their team consists of experienced scientists and biotech entrepreneurs committed to addressing significant health challenges.

21. SciNeuro Pharmaceuticals

• Website: scineuro.com
• Ownership type: Private Equity
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 62%, China 38%
• Latest funding: Series A, $100.0M, December 2020
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: scineuro-pharmaceuticals

SciNeuro Pharmaceuticals, based in Rockville, Maryland, is a biotechnology firm established in 2020. The company is dedicated to developing innovative therapeutics aimed at treating central nervous system (CNS) diseases. With a team of experienced scientists and industry leaders, SciNeuro is committed to translating scientific insights into transformative medicines. Their pipeline includes investigational therapies that target critical biological processes associated with various CNS conditions. The company has attracted significant investment, securing $100 million in Series A funding, which underscores its potential in the competitive pharmaceutical landscape. SciNeuro's strategic focus on addressing the challenges of CNS treatment positions it as a noteworthy entity in the pharmaceutical industry.

22. Deka Biosciences, Inc

• Website: dekabiosciences.com
• Ownership type: Venture Capital
• Headquarters: Germantown, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $29.9M, December 2023
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: deka-biosciences-inc

Deka Biosciences, Inc., based in Germantown, Maryland, is a biotechnology firm that specializes in developing personalized immunotherapy treatments aimed at addressing cancer and inflammatory diseases. Founded in 2018, the company leverages its proprietary Diakine™ platform, which combines various cytokines to create targeted therapies that enhance the immune system's ability to combat disease. Their approach is particularly notable for its focus on tailoring treatments to individual patients, which is increasingly important in modern medicine. Deka's primary customers include healthcare providers and patients seeking effective treatment options. The company has recently raised approximately $29.9 million in funding, reflecting investor confidence in their innovative approach and potential for future growth. With a dedicated team of professionals experienced in oncology and immunotherapy, Deka Biosciences is positioned to make significant contributions to the pharmaceutical industry.

23. AbelZeta

• Website: abelzeta.com
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 57%, China 43%
• Founded year: 2009
• Headcount: 201-500
• LinkedIn: cellular-biomedicine-group

AbelZeta Pharma, founded in 2009 and based in Rockville, Maryland, is a biopharmaceutical company dedicated to developing innovative T cell-based therapeutics aimed at treating cancer and immunological diseases. The company has a strong focus on hematological cancers and solid tumors, leveraging their research and development capabilities to create proprietary immune cell therapies. AbelZeta has made significant strides since treating its first oncology patient in 2015, including the licensing of two CD20-directed autologous CAR-T therapies to Janssen Biotech in 2023. Their approach emphasizes collaboration with multinational pharmaceutical companies to enhance patient access to their therapies. AbelZeta's pipeline includes promising candidates that have shown exceptional early clinical results, reflecting their commitment to advancing treatment options for patients with severe conditions.

24. ACI Biosciences

• Website: acibiosciences.com
• Ownership type: Private
• Headquarters: Chevy Chase, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2000
• Headcount: 11-50
• LinkedIn: animal-clinical-investigation

ACI Biosciences, founded in 2000 and based in Chevy Chase, Maryland, is a private research and development firm dedicated to advancing veterinary medicine and animal health. The company offers a range of product development services, including clinical trial management and regulatory support, aimed at improving health outcomes for animals. Their expertise lies in creating innovative therapeutic options and conducting clinical studies for various conditions affecting pets, particularly in oncology and internal medicine. ACI Biosciences collaborates with veterinarians, pet owners, and a network of clinical investigators to facilitate the development of new treatments. Their commitment to translational medicine highlights their goal of bridging research between species, ultimately benefiting both animals and humans. ACI Biosciences has not reported any funding, indicating a self-sustained operational model.

25. Neuraly Inc.

• Website: neuralymed.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $36.0M, July 2018
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: neuraly-inc

Neuraly Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, founded in 2016. The company is dedicated to developing revolutionary treatments for neurodegenerative diseases, including Parkinson's and Alzheimer's. Neuraly leverages cutting-edge scientific research to create disease-modifying therapies, primarily focusing on the activation of glial cells, which play a critical role in neuroinflammation and neuronal cell death. Their lead product, NLY01, is a GLP-1 receptor agonist that has shown promising results in preclinical models and is currently undergoing Phase 2 clinical trials. Neuraly has received significant funding, totaling $36 million in a Series A round in 2018, which supports their ongoing research and development efforts. As a subsidiary of D&D Pharmatech, Neuraly is part of a broader initiative to advance innovative medicines through specialized biotech companies.

Pharmaceuticals Companies Insights: Key Companies in Maryland

Want to Find More Pharmaceuticals Companies Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!